42 months; hazard ratio, 0.76; 95% CI, 0.63–0.91; P = 0.001), with a nonsignificant trend towards improvement in those with tumor expression of PD-L1 of 50% or more (median disease-free survival not reached in either arm; hazard ratio, 0.82; 95% CI, 0.57–1.18; P = 0.140).
← all excerpts
Perioperative systemic therapies for non-small-cell lung cancer: Recent advances and future perspectives.
1
—
—